Lexology February 25, 2025
Benesch Friedlander Coplan & Aronoff LLP

Private equity (PE) investment in the U.S. healthcare sector faces a complex and evolving regulatory and legislative landscape. Both federal and state authorities are intensifying scrutiny of PE investment, driven by concerns about market consolidation, quality of care, corporate profiteering and lack of financial transparency. As “headwinds” mount, particularly at the state level, PE firms and the healthcare businesses in which they invest must be prepared to adapt their consolidation strategies.

Federal Regulation and Legislation Related to Healthcare PE Will Likely Decrease

At the federal level, agencies such as the Federal Trade Commission (FTC) and the Department of Justice (DOJ) have heightened their oversight of PE activities in healthcare in recent years. In March 2024, the FTC conducted a workshop...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Govt Agencies, Investments, States, Trends
Eikon raises $351M in one of the year’s largest biotech venture rounds
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
Quantum Computing And AI Can Share The Investor Limelight
Quibim: $50M Series A for Precision Medicine with AI-Powered Imaging Biomarkers
Perplexity AI launching $50 million venture fund to back early-stage startups

Share This Article